Zealand Pharma Hosts Conference Call on August 11 at 4 pm CET (10am ET) to Present Second Quarter Results for 2022
August 04 2022 - 8:00AM
Company announcement – No. 31 /
2022
Zealand Pharma Hosts Conference Call
on August 11 at
4 pm CET (10am ET) to Present
Second Quarter Results
for 2022
Copenhagen, DK and Boston, MA, U.S. August 4,
2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
20045078,) a biotechnology company focused on the discovery and
development of innovative peptide-based medicines, announced that
it will host a conference call on August 11, 2022 at 4 pm CET (10
am ET) following the announcement of results for the second quarter
of 2022.
Presenting during the call will be President and Chief Executive
Officer Adam Steensberg, Chief Medical Officer David Kendall, and
Senior Vice President and Chief Financial Officer Matt Dallas. The
presentation will be followed by a Q&A session. The conference
call will be conducted in English.
Telephone dial-in information and a unique personal access PIN
will be provided upon registration via the following link,
https://register.vevent.com/register/BI0687000737bf4bdda7d667f72d07be30.
A live audio webcast of the call, including an accompanying
slide presentation, will be available via the following
link, https://edge.media-server.com/mmc/p/xmmfib4z, and will
be accessible on the Investor section of Zealand’s website
(www.zealandpharma.com/investor). A recording of the event will be
available on the Investor section of Zealand’s website after the
call.
About Zealand Pharma A/SZealand Pharma A/S
(Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on
the discovery and development of peptide-based medicines. More than
10 drug candidates invented by Zealand have advanced into clinical
development, of which two have reached the market and three
candidates are in late-stage development. In addition, license
collaborations with Boehringer Ingelheim and AstraZeneca create
opportunities for more patients to potentially benefit from
Zealand-invented peptide investigational agents currently in
development.
Zealand was founded in 1998 and headquartered in Copenhagen,
Denmark, with a presence in the U.S. that includes Boston. For more
information about Zealand’s business and activities, please
visit http://www.zealandpharma.com.
Forward-Looking StatementThe above information
contains forward-looking statements that provide Zealand Pharma’s
expectations or forecasts of future events. Such forward-looking
statements are subject to risks, uncertainties and inaccurate
assumptions, which may cause actual results to differ materially
from expectations set forth herein and may cause any or all of such
forward-looking statements to be incorrect. If any or all of such
forward-looking statements prove to be incorrect, our actual
results could differ materially and adversely from those
anticipated or implied by such statements. All such forward-looking
statements speak only as of the date of this release and are based
on information available to Zealand Pharma as of the date of this
release.
Contacts:Anna
Krassowska, PhDVice President, Investor Relations & Corporate
CommunicationsZealand PharmaEmail: ank@zealandpharma.com
David Rosen (U.S. Media)Argot PartnersEmail:
media@zealandpharma.com
Zealand Pharma AS (NASDAQ:ZEAL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zealand Pharma AS (NASDAQ:ZEAL)
Historical Stock Chart
From Sep 2023 to Sep 2024